Logo Image
News|Articles|August 7, 2026

FDA Launches Small Dispenser Assessment, Grants DSCSA Exemptions

Listen
0:00 / 0:00

Key Takeaways

  • FDA is surveying DSCSA small dispensers (≤25 FTE) to quantify capability gaps in exchanging package-level transaction data required for end-to-end traceability and verification across trading partners.
  • Persistent barriers for smaller pharmacies include limited resources and infrastructure to support interoperable systems needed for package-level data exchange with manufacturers, distributors, and repackagers.
SHOW MORE

FDA is evaluating small pharmacies' package-level tracing capabilities while extending certain Drug Supply Chain Security Act exemptions to those dispensers through November 2027.

The FDA is launching an assessment of small dispensers' ability to conduct interoperable, package-level product tracing under the Drug Supply Chain Security Act (DSCSA), according to a notice from the agency's Center for Drug Evaluation and Research Office of Compliance.1 FDA is also issuing temporary related compliance exemptions.2

The assessment targets pharmacies with 25 or fewer full-time employees, a group FDA defines as small dispensers under the DSCSA framework.1 FDA is requesting that these dispensers complete an assessment survey by September 22, and it said dispensers may designate a separate entity, such as a consultant, to complete the survey on their behalf.

What Is FDA Assessing?

FDA said the DSCSA Assessment of Small Dispensers is designed to evaluate whether this segment of the pharmacy market can meet the law's interoperable tracing requirements at the package level.1 DSCSA, enacted to build an electronic, interoperable system for tracing prescription drugs through the US supply chain, requires trading partners, including dispensers, to exchange transaction data down to the package level so products can be traced and verified.

Package-level tracing has been a persistent implementation challenge across the supply chain, particularly for smaller pharmacies with fewer resources to build or adopt the systems needed to exchange and verify that data with manufacturers, wholesale distributors and repackagers.

What DSCSA Exemptions Is FDA Granting?

Alongside the assessment, FDA is issuing exemptions from certain Section 582 requirements of the Food, Drug and Cosmetic Act to small dispensers, and where applicable, their trading partners, effective until November 27, 2027.2 FDA said the exemption period is meant to provide time to complete the assessment, publish a final assessment report for public comment and hold a public meeting on the findings.

“FDA urges small dispensers to continue their efforts to implement the necessary measures to comply with the enhanced drug distribution security requirements. Small dispensers and their trading partners who utilize these exemptions do not need to submit anything to FDA or inform the agency,” the agency bulletin states.2

What Should Small Dispensers Do Now?

Small dispensers eligible for the assessment should plan to complete FDA's survey ahead of the September 22 deadline, either directly or through a designated consultant.1 For the broader supply chain, the extended exemption means manufacturers, wholesale distributors and other trading partners might continue accommodating a segment of dispensers operating outside full package-level interoperability, for the time being.

References
  1. U.S. Food and Drug Administration. "Drug Supply Chain Security Act (DSCSA) Assessment of Small Dispensers." FDA.gov, 2026. https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/drug-supply-chain-security-act-dscsa-assessment-small-dispensers
  2. U.S. Food and Drug Administration. "Exemptions Under Drug Supply Chain Security Act." FDA.gov, 2026. https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act

Related Content